THE SMART TRICK OF ABBV-744 PRECLINICAL STUDIES AND RESULTS THAT NOBODY IS DISCUSSING

In Phase C, members will receive ABBV-744 and oral navitoclax. In Section D, contributors will obtain ABBV-744 and ruxolitinib. Members will acquire treatment until finally illness progression or maybe the participants are not able to tolerate the study drugs.Doable new ways to the prognosis and treatment of AML. (A) The identification of Tremendou